PCA
CTKB icon

Pallas Capital Advisors’s Cytek Biosciences CTKB Stock Holding History

Pallas Capital Advisors’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$58.8K Sell
13,464
-489
-4% -$2.31K ﹤0.01% 824
2025
Q4 		$70.5K Sell
13,953
-452
-3% -$2.1K ﹤0.01% 857
2025
Q3 		$50K Buy
14,405
+336
+2% +$1.26K ﹤0.01% 848
2025
Q2 		$47.8K Buy
+14,069
New +$46.9K ﹤0.01% 828

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Topline Capital Management Santa Monica, California $605M AUM 26.24% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Pallas Capital Advisors's CTKB Position: Q1 2026 in Review

Pallas Capital Advisors reduced its Cytek Biosciences (CTKB) stake by 3.5% in Q1 2026, selling an estimated $2.31K and leaving 13,464 shares worth $58.8K. The position accounts for ﹤0.01% of the portfolio, ranked #824.

Pallas Capital Advisors first reported a position in CTKB in Q2 2025 and has held it in 4 quarters since. The position peaked at $70.5K in Q4 2025. 165 funds tracked by Wall St. Rank hold CTKB as of Q1 2026.

  • Pallas Capital Advisors held 13,464 shares of Cytek Biosciences worth $58.8K as of Q1 2026.
  • Pallas Capital Advisors sold 489 Cytek Biosciences shares in Q1 2026, an estimated $2.31K.
  • Cytek Biosciences made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q1 2026, its #824 holding.
  • Pallas Capital Advisors first reported a position in Cytek Biosciences in Q2 2025 and has held it in 4 quarters since.
  • Pallas Capital Advisors's Cytek Biosciences position peaked at $70.5K in Q4 2025.
  • 165 funds tracked by Wall St. Rank held Cytek Biosciences as of Q1 2026.

Based on Pallas Capital Advisors's 13F filing for Q1 2026, filed 21 Apr 2026.